• Werewolf Therapeutics posted a first-quarter net loss of USD 13.5 million, narrowing from USD 18.1 million a year earlier, with loss per share improving to USD 0.28 from USD 0.40.
• Research and development expense fell to USD 8.2 million from USD 13.1 million, while general and administrative expense edged up to USD 5.1 million from USD 4.9 million.
• Cash and cash equivalents declined to USD 46.5 million as of March 31 from USD 57.1 million at year-end 2025.
• Entered an asset purchase agreement with Jazz Pharmaceuticals Ireland under which Jazz acquired exclusive global development and commercialization rights to JZP898, an IFNα program previously licensed under a 2022 deal.
• Repaid all amounts owed under its May 2, 2024 loan and security agreement with K2 HealthVentures as of May 6; management said it continues to explore strategic alternatives to maximize shareholder value and plans to update cash runway guidance in the near future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071605PRIMZONEFULLFEED9715797) on May 07, 2026, and is solely responsible for the information contained therein.